{"filing":{"accession_number":"0001437749-26-033045","cik":"0001131343","ticker":"PRNAF","company_name":"ALTERITY THERAPEUTICS LTD","form":"6-K","filing_date":"2026-10-21","report_date":"2026-10-31","primary_document":"athe20261021_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131343/000143774926033045/athe20261021_6k.htm"},"events":[{"id":36540,"run_id":33688,"accession_number":"0001437749-26-033045","anchor_item_number":"EX-99.1","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The exhibit discloses material changes to the remuneration package for Dr David Stamler, the Company's Chief Executive Officer and Managing Director, effective 15 October 2026. The announcement details revised base salary (US$525,000), STI arrangements, severance terms, and change-of-control provisions, with the Board noting it has approved these changes and intends to seek shareholder approval for termination benefits at the upcoming annual general meeting. This is a classic executive compensation disclosure under the governance domain.","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-10-21","form":"6-K","submitted_at":null,"items":[{"id":40993,"accession_number":"0001437749-26-033045","item_number":"EX-99.1","item_title":"ex_1028815.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses material changes to the remuneration package for Dr David Stamler, the Company's Chief Executive Officer and Managing Director, effective 15 October 2026. The announcement details revised base salary (US$525,000), STI arrangements, severance terms, and change-of-control provisions, with the Board noting it has approved these changes and intends to seek shareholder approval for termination benefits at the upcoming annual general meeting. This is a classic executive compensation disclosure under the governance domain.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:07:37.591506+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40993,"accession_number":"0001437749-26-033045","item_number":"EX-99.1","item_title":"ex_1028815.htm","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses material changes to the remuneration package for Dr David Stamler, the Company's Chief Executive Officer and Managing Director, effective 15 October 2026. The announcement details revised base salary (US$525,000), STI arrangements, severance terms, and change-of-control provisions, with the Board noting it has approved these changes and intends to seek shareholder approval for termination benefits at the upcoming annual general meeting. This is a classic executive compensation disclosure under the governance domain.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-21T10:07:37.591506+00:00","company_name":"ALTERITY THERAPEUTICS LTD","ticker":"PRNAF","filing_date":"2026-10-21"}]}